Peter Hammerman

Chief Scientific Officer at MOMA Therapeutics

A leading cancer biologist and oncologist, Dr. Hammerman joined MOMA from Novartis Institutes of Biomedical Research, where he was global head of oncology translational research.

At Novartis, Dr. Hammerman led a global team of 100 full-time employees focused on the discovery and development of novel cancer therapies, including small molecules, biologics and immunotherapeutics. Previously, he spent more than eight years as a physician scientist at the Dana-Farber Cancer Institute, where he trained in medical oncology and then served as an assistant professor. While there, he led a translational research laboratory focused on experimental therapeutics, genomics and biomarker development in lung and head and neck cancers and was actively involved in clinical trials in these areas based on his laboratory research. Dr. Hammerman was a recipient of multiple grants from the federal government and private foundations and has published more than 100 peer reviewed manuscripts. Before his time at Dana-Farber, Dr. Hammerman completed his internal medicine residency at Massachusetts General Hospital. Board certified in internal medicine and medical oncology, Dr. Hammerman holds a Ph.D. in cell and molecular biology from the University of Pennsylvania, an M.D. from the University of Pennsylvania School of Medicine and a Bachelor’s degree in biological sciences and history from Stanford University.

Links

Previous companies

Massachusetts General Hospital logo

Timeline

  • Chief Scientific Officer

    May, 2021 - present